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ABSTRACT 
Pemetrexed disodium is used for the treatment of malignant pleural mesothelioma and lung cancer. In the present study a simple stability 
indicating RP-HPLC method was developed and validated for the determination of Pemetrexed disodium. The process related substances 
such as Dimer-1 impurity, Dimer-2 impurity, N-Methyl Pemetrexed, Pemetrexed diethyl ester, Alanine derivative of Pemetrexed, DMF 
derivative of Pemetrexed, Acid intermediate, Oxidation impurity and D-isomer were separated on gradient mode and quantified. Forced 
degradation studies were performed to prove the specificity. Hypersil BDS C18 100 x 4.6mm, 3µm was used for the separation (at 27°C) with 
mobile phase mixture consisting of (0.02M sodium dihydrogen phosphate with 0.1% HCOOH and pH 3.8 with dilute sodium hydroxide): 
Acetonitrile (40:60 v/v) (pH 3.8) with a flow rate of 1.2 mL/min. Methanol: water (1:1) was used as diluent and the eluted compounds were 
monitored at 240 nm. 0.5-1500 µg/mL with linear regression equation y = 20588x - 9294.1 (R2=0.9999). The degradation products observed 
during the forced degradation studies were well resolved from the drug peak and proving that the method is a stability-indicating method. The 
method was validated as per ICH guidelines. 
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INTRODUCTION 
Pemetrexed disodium was approved for the treatment lung 
cancer1-3 either alone or in combination with other drugs. 
Pemetrexed disodium was quantified by using techniques 
such as LC-MS/MS4-5 in human plasma, HPLC in human 
plasma and urine6 UPLC7 in lyophilized parenteral 
formulation, Chiral liquid chromatography8-9, HPLC10-12 
methods for related substances13, spectrophotometric 
methods14-15, electrochemical method16 in the literature. In 
the present study the authors have developed a simple 
stability indicating RP-HPLC method for the determination 
of Pemetrexed disodium and also for the determination of 
process related substances using Waters Alliance 2695 
series HPLC system with 2998 photodiode array detector 
and the method was validated as per ICH guidelines. The 
process related substances such as Dimer-1 impurity, Dimer-
2 impurity, N-Methyl Pemetrexed, Pemetrexed diethyl ester, 
Alanine derivative of Pemetrexed, DMF derivative of 
Pemetrexed, Acid intermediate, Oxidation impurity and D-
isomer were separated on gradient mode and quantified. 
Forced degradation studies were performed to prove the 
specificity of the method. The chemical structures of 
Pemetrexed disodium and that of the process related 
substances were shown in Figure 1. 
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(Pemetrexed disodium) 
Disodium salt of (2S)-2-[[4-[2-(2-amino-4-oxo-3,7-
dihydropyrrolo [2,3-d] pyrimidin-5-yl) ethyl] benzoyl] amino] 
pentanedioate  
(N-methyl Pemetrexed) 
N-Methyl-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo [2,3-d] 
pyrimidin-5-yl) ethyl] benzoyl]-L-glutamic acid disodium 
  
(Oxidation impurity) 
4-[2-(2-amino-4,6-dioxo-4,5,6,7-tetrahydro-3H-pyrrolo[2,3- 
d] pyrimidin-5-yl)ethyl]benzoyl-L-glutamic acid  
(Alanine derivative of Pemetrexed) 
2-[({4-[2-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo-[2,3-d] 
pyrimidin-5-yl)- ethyl] phenyl} carbonyl) amino]-propanoic acid  
  
(Dimer-1 impurity) 
N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d] 
pyrimidin-5-yl) ethyl] benzoyl]-L-glutamic acid-γ-dimer  (DMF derivative of Pemetrexed) N-[4-[2-(2-{[-(Dimethylamino)-methylidene] amino}-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]-pyrimidine-5-yl) ethyl] 
benzoyl]-L-glutamic acid disodium salt  
 
 
(Pemetrexed diethyl ester) 
N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H pyrrolo[2,3-d] 
pyrimidin- 5-yl) ethyl] benzoyl]-L-glutamic acid diethyl ester  
(Dimer-2 impurity) 
N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d] 
pyrimidin-5-yl) ethyl] benzoyl]-L-glutamic acid-α-dimer  
   
(D-Isomer impurity) 
N-[4-[2-(2-Amino-4, 7-dihydro-4-oxo-1H-pyrrolo [2, 3-d] 
pyrimidin-5-yl) ethyl] benzoyl]-D-glutamic acid disodium 
hemi pentahydrate  
(Acid intermediate) 
4- [2-(2-Amino-4,7-dihydro-4-Oxo-1H-pyrrolo [2,3-d] 
pyrimidin-5-yl) ethyl] benzoic acid  
Figure 1: Chemical structures of Pemetrexed disodium and its process related substances 
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MATERIALS AND METHODS 
Pemetrexed disodium and its process related substances 
were procured from the local pharmaceutical company as 
gift samples. HPLC grade acetonitrile, methanol, formic acid, 
TFA, sodium hydroxide, hydrochloric acid, sodium 
dihydrogen phosphate, ammonium formate and hydrogen 
peroxide were purchased from Merck (India). Stock 
solutions containing Pemetrexed disodium and its process 
related substances were prepared in acetonitrile and diluted 
using diluent and stored.  
Chromatographic conditions 
Pemetrexed disodium and its process related substances 
such as Dimer-1 impurity, Dimer-2 impurity, N-Methyl 
Pemetrexed, Pemetrexed diethyl ester, Alanine derivative of 
Pemetrexed, DMF derivative of Pemetrexed, Acid 
intermediate, Oxidation impurity and D-isomer were 
separated on gradient mode and quantified using Hypersil 
BDS C18 (100 x 4.6mm, 3µm) column for separation and 
quantification using a mixture of mobile phase A (Buffer) 
consisting of 0.02M sodium dihydrogen phosphate with 0.1% 
HCOOH (pH adjusted to 3.8 with dilute sodium hydroxide) 
and mobile phase B consisting of buffer and acetonitrile in 
the ratio 40:60, v/v with flow rate of 1.2 mL/min (at 27°C). 
Methanol: water (1:1) was used as diluent. Waters Alliance 
2695 series HPLC system with 2998 photodiode array 
detector and the detector was monitored at 240 nm. 
Method validation17 
Linearity 
A series of Pemetrexed disodium solutions (0.5-1500 µg/mL) 
were prepared spiked with 0.15% process related 
substances and ͳͲ μL of these solutions were injected in to 
the HPLC system and the peak area was noted. A series of 
solutions were also prepared containing Oxidation impurity, 
Dimer impurity, N-Methyl Pemetrexed, Alanine derivative of 
Pemetrexed, DMF derivative of Pemetrexed, Acid 
intermediate and Pemetrexed diethyl ester standard solution 
at different concentrations at LOQ level, 0.05%, 0.075%, 
0.10%,0.12%,0.15%, 0.18%, and 0.225% w.r.t. the working 
concentration and Pemetrexed disodium standard solution 
were prepared at different concentrations at LOQ level, 
0.05%, 0.075%, 0.10%, 0.12%, 0.15%, 0.18%, 0.225%, 70%, 
80%, 90%, 100%, 110%, 120% and 130% w.r.t. the working 
concentration by performing appropriate dilutions to 
achieve the targeted concentrations. The linearity graph 
(calibration curve) was drawn with concentration of solution 
on the x-axis and mean peak area on the y-axis.  
Precision, Accuracy and Robustness 
Precision study was performed at its LOQ level. Six replicate 
sample solutions of Pemetrexed disodium (1.0 mg/mL) 
containing 0.15% of Oxidation impurity, Dimer impurity, N-
Methyl Pemetrexed, Alanine derivative of Pemetrexed, DMF 
derivative of Pemetrexed, Acid intermediate and Pemetrexed 
diethyl ester with respect to the sample concentration were 
prepared and each spiked sample solution was injected, peak 
area was noted and the % RSD was calculated. Accuracy was 
studied at LOQ level. Three different sample solutions (1.0 
mg/mL) of Pemetrexed disodium containing Oxidation 
impurity, Dimer impurity, N-Methyl Pemetrexed, Alanine 
derivative of Pemetrexed, DMF derivative of Pemetrexed and 
Acid intermediate, Pemetrexed diethyl ester were prepared 
at LOQ level and injected each solution once in to the system. 
The peak area of Oxidation impurity, Dimer impurity, N-
Methyl Pemetrexed, Alanine derivative of Pemetrexed, DMF 
derivative of Pemetrexed, Acid intermediate and Pemetrexed 
diethyl ester % recovery was calculated. Robustness of the 
method was evaluated by deliberately altering the method 
conditions from the original method parameters and 
verifying compliance of the system suitability requirements. 
Forced degradation studies18 
The stability indicating nature of the methods were 
determined by forced degradation of the drug substance 
samples using the following conditions such as base 
hydrolysis, acid hydrolysis, oxidation, thermal degradation 
and photo degradation. About 500.23 mg of Pemetrexed 
disodium sample was weighed accurately for the preparation 
of stock solution and transferred into a 50 mL volumetric 
flask, dissolved and diluted to volume with diluent and 
mixed.  
Base hydrolysis  
For related substances and assay test, 5.0 mL of stock 
solution was transferred in to a 50 mL volumetric flask and 
5.0 mL of 1N NaOH solution was added. This solution was 
kept for 24 hrs at room temperature and 5 mL of 1N HCl 
solution was added to this solution and diluted to volume 
with diluent and mixed. For D-isomer content test, 
Pemetrexed disodium sample was weighed and transferred 
into a volumetric flask, 1.0 mL of 0.5N NaOH solution was 
added, kept for 24 hrs at room temperature and then 
neutralised with 1.0 mL of 0.5N HCl solution and diluted to 
volume with diluent and mixed.  
Acid hydrolysis  
For related substances and assay test, 5.0 mL of stock 
solution was transferred in to a 50 mL volumetric flask and 
5.0 mL of 0.2N HCl solution was added. This solution was 
kept for 24 hrs at room temperature and 5 mL of 0.2N NaOH 
solution was added to this solution and diluted to volume 
with diluent and mixed. For D-isomer content test, 
Pemetrexed disodium sample was weighed and transferred 
into a volumetric flask, 1.0 mL of 0.1N HCl solution was 
added, kept for 24 hrs at room temperature and then 
neutralised with 1.0 mL of 0.1N NaOH solution and diluted to 
volume with diluent and mixed.  
Oxidation  
For related substances and assay test, 5.0 mL of stock 
solution was transferred in to a 50 mL volumetric flask and 
5.0 mL of 1.0% H2O2 solution was added. This solution was 
kept for 48 hrs at room temperature and after 48 hrs diluted 
to volume with diluent and mixed. For D-isomer content test, 
Pemetrexed disodium sample was weighed and transferred 
into a volumetric flask, 1.0 mL of 0.5% H2O2 solution was 
added, kept for 48 hrs at room temperature and after 48 hrs 
diluted to volume with diluent and mixed.  
Photo degradation 
About 0.5g of Pemetrexed disodium sample was weighed and 
transferred in to a petri dish and kept in photo stability 
chamber (1.2 million lux hours and 200 Watt Hrs/Sq.Mtr). 
For related substances and assay test, about 50 mg of photo 
degraded sample was transferred into a 50 mL of volumetric 
flask, dissolved and diluted to volume with diluent and 
mixed. For D-isomer content test, about 50 mg of photo 
degraded sample was transferred into a 10 mL of volumetric 
flask, dissolved and diluted to volume with diluent and 
mixed. 
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Thermal degradation 
About 0.5g of Pemetrexed disodium sample was weighed and 
transferred in to a petri dish and kept in oven at 60°C for 9 
days. For related substances and assay test, about 50 mg of 
thermal degraded sample was transferred into a 50 mL of 
volumetric flask, dissolved and diluted to volume with 
diluent and mixed. For D-isomer content test, about 50 mg of 
thermal degraded sample was transferred into a 10 mL of 
volumetric flask, dissolved and diluted to volume with 
diluent and mixed. 
Assay of Pemetrexed disodium injection 
Pemetrexed disodium is available with brand names ALIMTA  
(Label claim: 100 mg/vial & 500 mg); (Eli Lilly and Company, 
India) PEXATE  (Label claim: 100 mg/vial) (Miracalus 
Pharma Pvt Ltd), GIOPEM (Label claim: 100 mg/vial & 500 
mg/vial)  (GLS Pharma Ltd) as solution for injection. Two 
different brands were chosen and extracted with the mobile 
phase for the API and diluted as per the requirement and the 
percentage purity of Pemetrexed disodium was determined. 
RESULTS  
A simple and specific stability indicating gradient RP-HPLC 
method was developed and validated for the separation and 
quantification of Pemetrexed disodium and its related 
substances using Hypersil BDS C18 (100 x 4.6 mm, 3µm) 
column with flow rate 1.2 ml/min within a run time of 55 
mins.  
Method optimization 
During optimization different columns and mobile 
compositions were used in trials with different flow rates 
and finally the method was optimized. The mobile phase A 
consists of a buffer solution containing 0.02M sodium 
dihydrogen phosphate with 0.1% HCOOH maintaining pH 3.8 
(adjusted with dilute sodium hydroxide). The mobile phase B 
consists of a mixture of buffer and acetonitrile in the ratio 
40:60, v/v and the detector was monitored at 240 nm. The 
observations and conclusions recorded during the trial runs 
were shown in Table 1. The chromatograms obtained during 
the trials as well as the optimized conditions were shown in 
Figure 2. 
 
Table 1: Method optimization 
Trial 
Mobile phase (v/v) / 
Flow rate (ml/min) / Detection 
wavelength (nm) 
Diluent 
Gradient 
program 
(T/%B) 
Observations and 
conclusions 
Figure 
1 
 
Inertsil ODS-2V (250 x 
4.6mm, 5µm) column 
(Buffer:Acetonitrile 90: 10):: 
Buffer:Acetonitrile 10: 90)/ 1.5 / 
240 Water: 
Acetonitrile: 
2% aq. TFA 
(90:10:0.1) 
0/8,  
15/15, 
20/25, 
25/25,  
26/8,  
40/8 
Base line drift was 
observed and some of 
the impurities were 
closely eluted with the 
main peak and no 
better resolution 
between the peaks. 
2A 
2B 
2 
Selection of diluent 
(Buffer:Acetonitrile, 90: 
10)::Buffer:Acetonitrile 10: 90) / 
1.5 / 240 
Acetonitrile: 
water (1:1) 
Methanol: 
water (1:1) 
 
 
 
 ” 
Pemetrexed peak 
shape was distorted in 
presence of 
Acetonitrile i.e. peak 
splitting was observed 
Therefore diluent was 
changed. 
2C 
2D 
2 
Selection of 
wavelength 
(Buffer:Acetonitrile 90: 10):: 
Buffer:Acetonitrile 10: 90)/ 1.5 / 
240 
Methanol: 
water (1:1) 
 
 ” 
Base line drift was 
more at 225 nm than 
at 240 nm. Unknown 
impurities were 
observed at 240 nm.  
2E 
2F 
4 
Selection of buffer and 
pH 
0.02 M Ammonium formate 
buffer was used with  pH 2.5, 2.8 
and 4.5 
”  Optimum pH 2.8 was selected as all the 
peaks were resolved. 
2G 
2H 
2I 
5 
Mobile phase 
composition 
optimization 
(0.02M Ammonium formate (pH 
2.8 adjusted with formic acid): 
(Buffer: Acetonitrile [100: 
920:70)] / 1.2 / 240 ” 
0/20, 5/20, 
20/50, 
5/50, 
50/80, 
5/80, 
56/20, 
60/20 
Two impurities were 
eluted closely i.e. at 
4.2 min and 4.5 min. 
Impurity observed at 
4.2 min is a process 
related impurity.  
2J 
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6 
Flow rate, Mobile 
phase B and gradient 
program were 
changed 
Buffer: (Buffer, Methanol and 
Acetonitrile) [100: (25:20:55)] / 
1.5 / 240 
 ” 
0/20, 5/20, 
15/25, 
0/25, 
20/60, 
0/60, 
45/80, 
6/20, 
50/20 
Impurity observed at 
9.2 min is a 
combination of two 
peaks. and two peaks 
at 9.8 and 10.5 min 
Impurities  at 4.2 and 
4.5 min were not 
separated completely. 
2K 
7 
Buffer strength was 
enhanced from 0.02 M 
to 0.05 M 
 
 
 ”  ” ” 
Impurity observed at 
4.2 and 4.5 min were 
well resolved but 
Pemetrexed peak 
shape was not 
symmetric. Resolution 
was 1.2 and 
theoretical plates 
were 17000. 
2L 
8 
Trifluoro acetic acid 
(TFA) was introduced 
in to mobile phase. 
 
0.05M Ammonium formate with 
0.1% TFA (pH adjusted to 2.8 
with formic acid) ” ” 
The Dimer-2 impurity 
was co-eluted along 
with Pemetrexed 
peak. Resolution was 
improved (i.e. from 
1.2 to 2.1) and 
theoretical plates 
were 18650. 
2M 
9 
Pemetrexed was 
spiked with 0.15% of 
all impurities. 
0.05M Ammonium formate with 
0.1% TFA (pH adjusted to 2.8 
with HCOOH) ” 0/17, 20/17, 50/80, 
25/17, 
60/17 
All impurities were 
well resolved. 
Resolution between 
Pemetrexed and 
Dimer-2 obtained was 
2.15. 
2N 
10 
Pemetrexed was 
spiked with 0.15% of 
all impurities. 
Selection of Hypersil BDS C18 
(100 x 4.6 mm, 2µm) column / 1.2 ” 0/15, 15/15, 45/50, 
50/15, 
55/15 
Resolution between 
Pemetrexed and 
Dimer-2 was 2.20 but 
baseline drift was 
observed. 
2O 
11 
Volatile buffer was 
replaced with 
phosphate buffer 
Buffer [0.02M Sodium dihydrogen 
phosphate with 0.1% HCOOH (pH 
adjusted to 3.8 with dil NaOH)]: 
[Buffer: Acetonitrile, 40:60] 
” ” Baseline drift was reduced and resolution was 2.06. 
(Method optimized) 
2P 
 
Method validation 
Linearity 
Pemetrexed disodium has shown linearity over the 
concentration range 0.5-1500 µg/mL with linear regression 
equation y = 20588x - 9294.1 (R2=0.9999) (Table 2) and the 
calibration curve was shown in Figure 3. Good linearity 
response was also obtained for Pemetrexed disodium peak 
over the concentration ranges of LOQ to 0.225% and LOQ to 
130% w.r.t. the working concentration (Table 3). The 
linearity of related substances was shown in Table 4 and the 
corresponding regression equations along with the relative 
response factors were shown in Table 5. The method 
covered the range 0.1668 - 2.2751 µg/mL for Oxidation 
impurity, 0.2704 - 2.2640 µg/mL for Dimer impurity, 0.1811 
-  2.1849 µg/mL for N-Methyl Pemetrexed, 0.1674 - 2.2757 
µg/mL for Alanine derivative of Pemetrexed, 0.0997 - 2.2604 
µg/mL for DMF derivative of Pemetrexed, 0.0989 - 2.2443 
µg/mL for Acid intermediate and 0.1447 - 2.2716 µg/mL for 
Pemetrexed diethyl ester. Good linearity response was 
obtained for Pemetrexed disodium and its related 
substances and the correlation coefficient of linear 
regression equations was not less than 0.98 for each 
Impurity and Pemetrexed disodium.  
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Figure 2A: Chromatogram of blank 
 
Figure 2B: Chromatogram of Premetrexed (Trial 1) 
 
Figure 2C: Chromatogram of Premetrexed in Acetonitrile and water (1:1) as diluent (Trial 2) 
 
Figure 2D: Chromatogram of Premetrexed in Methanol and water (1:1) as diluent (Trial 2) 
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Figure 2E: Chromatogram of Premetrexed at 240 nm (Trial 2) 
 
Figure 2F: Chromatogram of Premetrexed at 225 nm (Trial 2) 
 
Figure 2G: Chromatogram of Premetrexed at buffer pH 4.5 (Trial 4) 
 
Figure 2H: Chromatogram of Premetrexed at buffer pH 2.5 (Trial 4) 
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Figure 2I: Chromatogram of Premetrexed at buffer pH 2.8 (Trial 4) 
 
Figure 2J: Chromatogram of Premetrexed (Mobile phase composition changed) (Trial 5) 
 
Figure 2K: Chromatogram of Premetrexed (Flow rate, mobile phase composition and gradient program changed) 
(Trial 6) 
 
Figure 2L: Chromatogram of Premetrexed (Buffer strength enhanced from 0.02 to 0.05 M (Trial 7) 
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Figure 2M: Chromatogram of Premetrexed (TFA introduced in to mobile phase) (Trial 8) 
 
Figure 2N: Chromatogram of Premetrexed spiked with 0.15% of all impurities  
(Gradient program modified) (Trial 9) 
 
Figure 2O: Chromatogram of Premetrexed spiked with 0.15% of all impurities  
(Column and flow rate changed) (Trial 10) 
 
Figure 2P: Chromatogram of Premetrexed spiked with 0.15% of all impurities  
(Volatile buffer replaced with phosphate buffer) (Trial 11) (Method optimized) 
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Table 2: Linearity of Pemetrexed disodium 
Conc.  (µg/mL) Mean peak area 
0.5 10802 
1 22174 
1.5 22129 
5 108968 
50 1021849 
100 2049502 
200 4099121 
400 8201269 
500 10224220 
800 16400710 
1000 20484088 
1200 24952028 
1500 20787406 
Slope 20588 
y-intercept -9294.1 
Correlation coefficient 0.9999 
 
 
Table 3: Linearity results of Pemetrexed disodium 
LOQ to 0.225% w.r.t working conc. 
Conc. (µg/mL) Peak area 
0.2222 6594 
0.4356 11600 
0.6600 17375 
0.8843 23222 
1.0559 27279 
1.3199 34191 
1.5839 41159 
1.9799 51241 
Regression equation 25511+ 620 (r2 = 0.9999) 
LOQ to 130% w.r.t working conc. 
626.2505 14379381 
715.7149 16562547 
805.1792 18670056 
894.6436 20593974 
984.1080 22666881 
1073.5723 24529007 
1163.0367 26683259 
Regression equation 22982 + 12315 (r2 = 1.0000) 
 
Table 4: Linearity of related substances of Pemetrexed disodium 
Oxidation 
impurity 
Dimer 
impurity 
N-methyl 
Pemetrexed 
Alanine 
derivative of 
Pemetrexed 
DMF 
derivative of 
Pemetrexed 
Acid 
intermediate 
Pemetrexed 
diethyl ester 
Conc. 
(µg/mL) 
Peak 
area 
Conc. 
(µg/mL) 
Peak 
area 
Conc. 
(µg/mL) 
Peak 
area 
Conc. 
(µg/mL) 
Peak 
area 
Conc. 
(µg/mL) 
Peak 
area 
Conc. 
(µg/mL) 
Peak 
area 
Conc. 
(µg/mL) 
Peak 
area 
0.1668 2692 0.2704 4050 0.1811 4418 0.1674 4106 0.0997 2665 0.0989 3442 0.1447 3216 
0.5005 8680 0.4981 7290 0.4807 11764 0.5006 12182 0.4973 13407 0.4937 16975 0.4998 10711 
0.7584 13131 0.7547 11268 0.7283 18084 0.7586 19222 0.7535 20377 0.7481 25615 0.7572 16299 
1.0162 17629 1.0112 14894 0.9759 24315 1.0165 26011 1.0096 27558 1.0025 33731 1.0146 21782 
1.2134 20898 1.2074 17349 1.1653 28790 1.2137 30709 1.2055 32956 1.1970 40213 1.2115 25853 
1.5167 26244 1.5093 22579 1.4566 36362 1.5171 39088 1.5069 41608 1.4962 51089 1.5144 32472 
1.8200 31339 1.8112 26747 1.7479 43899 1.8205 46473 1.8083 49972 1.7954 61420 1.8173 39028 
2.2751 38907 2.2640 34089 2.1849 55105 2.2757 57815 2.2604 61055 2.2443 77226 2.2716 48640 
 
Table 5: Linearity (Regression equations) of related substances 
Analyte name Regression equation Relative response factor (RRF) 
Oxidation impurity Y = 17171x + 49 (0.9999) 1.63 
Dimer impurity Y = 15002x - 206 (0.9996) 1.90 
N-Methyl Pemetrexed Y = 25299x - 369 (0.9999) 1.11 
Alanine derivative of Pemetrexed Y = 25648x - 269 (0.9999) 1.05 
DMF derivative of Pemetrexed Y = 27326x - 24 (0.9998) 0.93 
Acid intermediate Y = 34316x - 218 (0.9999) 0.74 
Pemetrexed diethyl ester Y = 21389x + 69 (1.0000) 1.19 
 
 
 
Figure 3: Calibration curve of Pemetrexed disodium 
 
Limit of Detection and Limit of Quantitation (LOD and 
LOQ) 
LOD and LOQ were established by injecting diluted 
solutions having known concentration of Pemetrexed 
disodium, Oxidation impurity, Dimer impurity, N-Methyl 
Pemetrexed, Alanine derivative of Pemetrexed, DMF 
derivative of Pemetrexed, Acid intermediate and 
Pemetrexed diethyl ester to obtain a signal to noise ratio of 
greater than or equal to 3 and 10 for LOD and LOQ 
respectively (Table 6). 
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Table 6: LOD and LOQ of Pemetrexed disodium and its 
related substances 
Analyte name LOD LOQ 
Pemetrexed disodium 0.0738 0.2239 
Oxidation impurity 0.0550 0.1668 
Dimer impurity 0.0892 0.2704 
N-Methyl Pemetrexed 0.0597 0.1811 
Alanine derivative of Pemetrexed 0.0552 0.1674 
DMF derivative of Pemetrexed 0.0322 0.0977 
Acid intermediate 0.0326 0.0989 
Pemetrexed diethyl ester 0.0477 0.1447 
 
Precision at LOQ level 
The RSD at LOQ level was obtained as 3.1% for Pemetrexed 
disodium, 8.5% for Oxidation impurity, 2.9% for Dimer 
impurity, 3.1% for N-Methyl Pemetrexed, 2.5% for Alanine 
derivative of Pemetrexed, 3.2% for DMF derivative of 
Pemetrexed, 4.9% for Acid intermediate and 2.7% for 
Pemetrexed diethyl ester indicating that the acceptance 
criteria was achieved. Acceptable criteria mean that the RSD 
at LOQ level should not be more than 15.0% for each analyte 
(Table 7). 
 
Table 7: Precision study of Pemetrexed disodium and its related substances 
S. No. 
Peak area 
Pemetrexed 
disodium 
Oxidation 
impurity 
Dimer 
impurity 
N-Methyl 
Pemetrexed 
Alanine 
derivative of 
Pemetrexed 
DMF derivative 
of Pemetrexed 
Acid 
intermediate 
Pemetrexed 
diethyl ester 
1 6844 2873 3858 4216 4292 3132 3352 3110 
2 6656 2426 3871 4275 4134 3080 3478 3201 
3 6542 2849 4011 4528 4044 3133 3131 3022 
4 6858 2434 4068 4541 4266 3201 3049 3122 
5 6760 2948 4150 4310 4183 3099 3284 3196 
6 6318 2633 4077 4351 4049 3358 3367 3267 
Mean 6663 2694 4006 4370 4161 3167 3277 3153 
RSD 3.1% 8.5% 2.9% 3.1% 2.5% 3.2% 4.9% 2.7% 
 
Accuracy  
The recovery obtained (at LOQ level) was in the range of 
100.8% - 113.7% for Oxidation impurity, 109.5% - 112.6% 
for Dimer impurity, 105.0% - 112.2% for N-Methyl 
Pemetrexed, 111.5% - 114.1% for Alanine derivative of 
Pemetrexed, 99.3% - 99.8% for DMF derivative of 
Pemetrexed, 114.4% - 116.1% for Acid intermediate and 
114.2% - 115.4% for Pemetrexed diethyl ester indicating 
that the acceptance criteria was fulfilled (Recovery should 
be within the range of 70.0 – 130.0%) (Table 8). 
 
Table 8: Accuracy of process related substances 
 
 
 
 
Name Workup 
Amount 
added (µg/mL) 
Amount                            
obtained (µg/mL) 
% 
Recovery 
% Mean  
recovery 
Oxidation impurity 
1 
0.1834 
0.2085 113.7 
109.0 2 0.2061 112.4 
3 0.1848 100.8 
Dimer impurity 
1 
0.3025 
0.3406 112.6 
110.6 
 
2 0.3313 109.5 
3 0.3315 109.6 
N-Methyl Pemetrexed 
1 
0.1911 
0.2233 112.2 
109.7 2 0.2091 105.0 
3 0.2230 112.0 
Alanine derivative 
1 
0.1774 
0.1978 111.5 
112.7 2 0.1994 112.4 
3 0.2024 114.1 
DMF derivative 
1 
0.0997 
0.0995 99.8 
99.6 2 0.0990 99.3 
3 0.0994 99.7 
Acid intermediate 
1 
0.0989 
0.1131 114.4 
115.4 2 0.1143 115.6 
3 0.1148 116.1 
Pemetrexed diethyl ester 
1 
0.1447 
0.1653 114.2 
115.0 2 0.1668 115.3 
3 0.1670 115.4 
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Robustness  
The effect of flow rate, column temperature, buffer pH, 
mobile phase composition on system suitability were 
summarized in Table 9. Pemetrexed disodium was well 
separated from the related substances such as acid 
intermediate, alanine derivative of Pemetrexed, DMF 
derivative of Pemetrexed and Pemetrexed diethyl ester to 
prove that the method is specific (Figure 4).  
 
 
Chromatogram of Pemetrexed disodium with its process related substances 
 
Lower flow rate (1.1 mL/min) 
 
Higher flow rate (1.3 mL/min) 
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Higher column temperature (32°C) 
 
Lower column temperature (22°C) 
 
Mobile phase variation (Lower Organic) 
 
Mobile phase variation (Higher Organic) 
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Mobile phase variation (Lower Formic acid) 
 
Mobile phase variation (Higher Formic acid) 
 
Buffer pH variation (pH 3.6) 
 
Buffer pH variation (pH 4.0) 
Figure  4: Robustness study of Pemetrexed disodium in presence of its process related substances 
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Table 9: Robustness of Pemetrexed disodium and its process related substances 
Method 
Conditions 
Pemetrexed 
disodium 
Specificity Solution 
Tailing 
factor 
RT 
(mins) 
Relative retention time (RRT) 
Oxidation 
impurity 
Dimer 
impurity 
N-Methyl 
Pemetrexed 
Alanine 
derivative 
DMF 
derivative 
Acid 
intermediate 
Pemetrexed 
diethyl 
ester 
As per method 0.7 12.84 0.21 0.58 0.68 1.65 1.85 1.98 3.33 
Lower column 
temp. 22C 0.7 16.41 0.18 0.57 0.66 1.39 1.51 1.63 2.64 
Higher column 
temp. 32C 0.8 10.32 0.23 0.59 0.70 1.87 2.19 2.31 4.09 
Lower flow 
rate 1.1 
mL/min. 
0.7 14.00 0.21 0.58 0.68 1.57 1.74 1.86 3.10 
Higher flow 
rate 1.3 
mL/min. 
0.7 11.81 0.21 0.58 0.68 1.73 1.96 2.09 3.57 
Lower organic 
ratio 
(44:56,v/v) 
0.7 15.47 0.19 0.58 0.68 1.47 1.62 1.73 2.90 
Higher organic 
ratio 
(36:64,v/v) 
0.7 9.76 0.24 0.58 0.70 1.89 2.24 2.43 4.17 
Lower Formic 
acid ratio 
0.7 13.25 0.21 0.58 0.68 1.63 1.81 1.93 3.26 
Higher Formic 
acid ratio 
0.7 12.60 0.21 0.58 0.69 1.68 1.88 2.02 3.41 
Lower buffer 
pH-3.6 
0.7 15.38 0.20 0.62 0.67 1.47 1.60 1.69 2.80 
Higher buffer 
pH-4.0 
0.8 10.65 0.23 0.55 0.72 1.84 2.16 2.33 4.04 
 
Assay of Pemetrexed disodium  
Two different brands of Pemetrexed disodium formulations 
were analyzed using the above optimized conditions and it 
was found that Pemetrexed disodium has shown 99.99-
101.45 purity range and no interference of excipients was 
observed. 
Forced degradation studies 
Pemetrexed disodium was preliminarily subjected to forced 
degradation studies using 0.2N NaOH for 60 hours (Basic 
degradation), 0.2N HCl for 80 hours (Acidic degradation), 
0.5% H2O2 for 7 hours (Oxidative degradation), UV at 254 
nm for 48 hours (Photolytic degradation) and 60°C for 48 
hours (Thermal degradation) with the above optimised 
method used for the assay method and the results were 
shown in Table 10. The peak purity and the purity threshold 
values observed during the forced degradation studies of 
Pemetrexed disodium conducted at an exaggerated 
condition were shown in Table 11 and the degradation 
results obtained for the related substances were shown in 
Table 12. The resultant chromatograms obtained during the 
degradation study of Pemetrexed disodium in presence of its 
related substances were shown in Figure 5. 
 
Table 10: Preliminary degradation results of Pemetrexed disodium 
Degradation condition Assay (%) 
Total 
impurities (%) 
Purity 
angle 
Purity  
threshold 
Pemetrexed 99.2 0.99 0.062 0.201 
Basic degradation 
(0.2N NaOH,60 h) 
98.9 0.95 0.055 0.299 
Acidic degradation 
 (0.2N HCl, 80 h) 
95.2 1.12 0.061 0.219 
Oxidative degradation 
 (0.5% H2O2, 7 h) 
101.8 4.04 0.092 2.175 
Photolytic degradation 
( UV at 254 nm, 48 h) 
99.2 0.96 0.054 0.210 
Thermal degradation 
 (60°C, 48 h) 
99.2 0.94 0.072 0.200 
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Table 11: Peak purity results of Pemetrexed disodium 
Degradation condition Purity angle Purity threshold 
Basic degradation (0.5N NaOH, 24 hrs) 0.224 0.401 
Acidic degradation (0.1N HCl, 24 hrs) 0.026 0.316 
Oxidative degradation (0.5% H2O2, 48 hrs) 0.026 0.307 
Photo degradation (1.2 million Lux hours and 200 Wat Hrs/Sq.Mtr) 0.128 0.347 
Thermal degradation (60°C, 9 days) 0.196 0.324 
 
 
 
Figure 5A: Chromatogram of blank 
 
Figure 5B: Chromatogram of Pemetrexed disodium 
 
Figure 5C: Chromatogram of NaOH blank 
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Figure 5D: Chromatogram of Pemetrexed disodium during basic degradation (0.5N NaOH) 
 
Figure 5E: Chromatogram of HCl blank 
 
Figure 5F: Chromatogram of Pemetrexed disodium during acidic degradation (0.1N HCl) 
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Figure 5G: Chromatogram of H2O2 blank 
 
Figure 5H: Chromatogram of Pemetrexed disodium during oxidative degradation (0.5% H2O2) 
 
Figure 5I: Chromatogram of Pemetrexed disodium during thermal degradation 
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Figure 5J: Chromatogram of Pemetrexed disodium during photolytic degradation 
 
Table 12: Degradation results of related substances of Pemetrexed 
Degradation results of related substances during base hydrolysis (0.5N NaOH) 
Degradation 
condition 
% 
D-
isomer 
% w/w 
Oxidation 
impurity 
% w/w 
Dimer 
impurity 
% w/w 
N-Methyl 
Pemetrexed 
% w/w 
Alanine 
derivative 
% w/w 
DMF 
derivative 
% w/w 
Acid 
intermediate 
% w/w 
Pemetrexed 
diethyl 
ester 
Control 0.01 0.05 0.07 0.01 0.01 0.04 0.01 
Below 
detection 
limit 
24 hrs 0.02 0.02 0.08 0.01 0.01 
Below 
detection 
limit 
0.04 
Below 
detection 
limit 
Degradation results of related substances during acidic hydrolysis (0.1N HCl) 
Control 0.02 0.06 0.08 0.01 0.01 0.03 0.01 
Below 
detection 
limit 
24 hrs 0.02 0.03 0.08 0.01 0.01 0.02 0.01 
Below 
detection 
limit 
 
Control 0.02 0.06 0.08 0.01 0.01 0.03 0.01 
Below 
detection 
limit 
48 hrs 0.01 7.33 0.06 0.01 0.01 0.03 0.01 
Below 
detection 
limit 
Degradation results of related substances during oxidation (0.5% H2O2) 
Control 0.02 0.06 0.08 0.01 0.01 0.03 0.01 
Below 
detection 
limit 
48 hrs 0.01 7.33 0.06 0.01 0.01 0.03 0.01 
Below 
detection 
limit 
Degradation results of related substances during photolysis (1.2 million lux hours and 200 Wat Hrs /Sq.Mtr) 
Control 0.01 0.05 0.07 0.01 0.01 0.04 0.01 
Below 
detection 
limit 
After 1.2 
million lux 
hours 
0.02 0.19 0.07 0.01 
Below 
detection 
limit 
0.04 
Below 
detection 
limit 
Below 
detection 
limit 
Thermal degradation results of related substances (60°C, 9 days) 
Control 0.01 0.05 0.07 0.01 0.01 0.04 0.01 
Below 
detection 
limit 
9 days 0.02 0.10 0.07 0.01 0.01 0.04 0.02 0.01 
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Specificity 
Specificity of the method was determined by injecting the 
analyte spiked with all the known components expected to 
be present in the drug substance. Separate solutions of 
diluent, Pemetrexed disodium, known impurities (Oxidation 
impurity, Dimer impurity,  Pemetrexed diethyl ester, DMF 
derivative of Pemetrexed, Alanine derivative of Pemetrexed, 
Acid intermediate and N-Methyl Pemetrexed) and a 
combined solution containing all the mentioned components 
were injected at 0.15% for Oxidation impurity, Dimer 
impurity,  Pemetrexed diethyl ester, DMF derivative of 
Pemetrexed, Alanine derivative of Pemetrexed, Acid 
intermediate and N-Methyl Pemetrexed into a HPLC. The 
peak of any substance in the given optimized conditions is 
considered to be spectrally pure if the purity angle is less 
than he purity threshold. Resolution between Pemetrexed 
disodium peak and nearby peak was not less than 1.5. 
Resolution obtained between Pemetrexed disodium and 
nearby peak is 4.6. Table 13 shows the retention time, 
relative retention time (RRT), relative response factor (RRF) 
and peak purities w.r.t. Pemetrexed disodium in the 
combined solution. 
 
  
Blank Pemetrexed disodium standard  
  
Pemetrexed disodium (As such solution) Oxidation impurity Standard Solution 
  
Dimer impurity Standard Solution N-Methyl Pemetrexed Standard 
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Alanine derivative of Pemetrexed Standard DMF derivative of Pemetrexed Standard 
  
Acid intermediate Standard Pemetrexed diethyl ester Standard 
 
Figure 6: Chromatograms of Pemetrexed disodium and its process related substances (Specificity) 
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Table 13: Specificity  
Component 
RT 
(min) 
Relative retention  
time (RRT) 
Relative response 
factor  
(RRF) 
Resolution 
Purity 
angle 
Purity  
threshold 
Pemetrexed disodium 14.57 1.00 --- 2.1 0.020 0.244 
Oxidation impurity  2.88 0.20 1.45 18.8 0.729 2.797 
Dimer-1 impurity 7.78 0.52 1.85 4.6 0.848 2.279 
N-Methyl Pemetrexed  11.24 0.78 1.02 4.6 1.886 2.425 
Dimer-2 impurity 16.57 1.14 1.14 2.1 0.214 0.564 
Alanine derivative of Pemetrexed 22.50 1.54 0.95 2.2 1.742 2.202 
DMF derivative of Pemetrexed 24.99 1.72 0.91 5.4 0.717 2.000 
Acid intermediate 27.09 1.86 0.72 2.6 0.492 2.222 
Pemetrexed diethyl ester 44.64 2.06 1.12 2.4 0.798 2.981 
  
DISCUSSION 
Pemetrexed disodium and its process related substances [N-
Methyl Pemetrexed, Pemetrexed diethyl ester, Alanine 
derivative of Pemetrexed, Dimer-1 impurity, Dimer-2 
impurity, DMF derivative of Pemetrexed, Acid intermediate, 
Oxidation impurity and D-isomer] were separated on 
gradient mode and quantified using using liquid 
chromatographic technique. This method has not been done 
till today in the literature and a brief summary of the 
analytical methods so far developed by authors was given in 
Table 14. (0.02M sodium dihydrogen phosphate with 0.1% 
HCOOH and pH 3.8 with dilute sodium hydroxide): 
Acetonitrile (40:60 v/v). The system suitability, specificity 
and other validation parameters were well in accordance 
with the ICH guidelines. 
 
Table 14: Comparison of published methods with the present method 
Method Mobile phase (v/v) Comment 
 
Ref 
Ultrafast and high-throughput 
MALDI-QqQ-MS/MS analysis 
Methotrexate internal standard 
- 
Human plasma 
 
4 
LC–MS/MS analysis 
Isotope-labelled internal standard 
- 
Human plasma 
Pemetrexed and its 
metabolites 
5 
HPLC 
Internal standard Lometrexol 
sodium formate buffer: acetonitrile Human plasma and urine 6 
UPLC 
 
0.1% ortho-phosphoric acid: Acetonitrile Stability indicating 7 
Chiral HPLC 
 
 
Hexane: Ethanol: Trifluoro acetic acid 
Separation of 
D and L-enantiomers 
8 
Chiral HPLC 
 
Hexane: Ethanol: Isopropyl alcohol: TFA 
(250:650:100:1) 
Separation and assay of 
Pemetrexed and its D 
isomer 
9 
HPLC 
0.1% v/v aq. phosphoric acid buffer: acetonitrile 
(85: 15) 
Stability indicating assay 10 
HPLC 
Phosphate buffer (pH adjusted to 6.5 with ortho 
phosphoric acid): acetonitrile (90: 10) 
Assay 11 
HPLC 
Acetonitrile: Phosphate buffer (pH adjusted to 3.0 
with ortho phosphoric acid): (35: 65) 
Assay 12 
HPLC 
Acetonitrile and buffer (pH adjusted to 5 with 
orthophosphoric acid) in the ratio (15:85) 
Assay and its related 
substances 
13 
 
HPLC 
 
Spectrophotometry 
20 mM Dibasic phosphate buffer (adjusted to pH 
6.50 with ortho-phosphoric acid) and acetonitrile 
(88:12) 
Distilled water 
Assay 14 
Spectrophotometry 
1,2-Napthoquinone-4-Sulphonic acid 
MBTH reagent 
PDAB reagent 
Assay 15 
Voltammetry technique Phosphate buffer pH 3 - pH 10 
Linearity ͳͲ μM to Ͳ.75 μM 16 
HPLC 
(Gradient mode) 
Buffer [0.02M sodium dihydrogen phosphate with 
0.1% HCOOH (pH adjusted to 3.8 with dil. NaOH)] : 
[Buffer: Acetonitrile (40:60) 
Linearity 
0.5-1500 µg/mL 
Pres
ent 
met
hod 
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CONCLUSIONS 
A simple and new stability indicating RP-HPLC method has 
been developed for the determination of Pemetrexed 
disodium and its related substances. The method was 
validated (ICH guidelines) by linearity, precision, accuracy 
and robustness and this method is highly helpful for the 
identification and quantification of impurities and related 
substances in injections as well as metabolic studies. The 
proposed method is specific and the system suitability 
parameters are within acceptable criteria.  
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